PYXS Company Profile and Key Details

Q: Who are the executives of PYXS?

Mr. John L. Flavin M.B.A., MBA, Ph.D.Co-Founder & Independent ChairmanDr. Jan Pinkas Ph.D.Chief Scientific OfficerMs. Martina Molsbergen B.S.Interim Chief Bus. OfficerDr. Lara S. Sullivan M.D., MBAChief Executive Officer, Pres & DirectorDr. Jay M. Feingold M.D., Ph.D.Chief Medical OfficerDr. Charles T. Gombar Ph.D.Senior Vice President of Portfolio & Program ManagementMr. Jitendra WadhaneChief Accounting Officer, Senior Vice President of Fin. & Corporation ControllerMs. Pamela Yanchik Connealy M.B.A.Chief Financial Officer & Chief Operating OfficerDr. Balu N. Balasubramanian Ph.D.Advisor

NASDAQ : PYXS

Pyxis Oncology

$3.04

0.39+14.72%

At Close 4:00 PM

55.38

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Pyxis Oncology, Inc. (PYXS) stock surged +14.72%, trading at $3.04 on NASDAQ, up from the previous close of $2.65. The stock opened at $2.70, fluctuating between $2.70 and $3.04 in the recent session.

Stock Snapshot

2.65

Prev. Close

192.6M

Market Cap

2.7

Day Low

-2.32

P/E Ratio

-1.31

EPS (TTM)

-1.73

Cash Flow per Share

2.7

Open

63.36M

Number of Shares

3.04

Day High

65.8%

Free Float in %

2.81

Book Value

1.12M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Aug 03, 2026	2.70	3.04	2.70	3.04	1.12M
Jul 31, 2026	2.84	2.85	2.63	2.65	749.2K
Jul 30, 2026	2.95	3.00	2.81	2.87	638.3K
Jul 29, 2026	2.90	3.09	2.89	2.92	943.05K
Jul 28, 2026	2.90	3.05	2.74	2.91	1.72M
Jul 27, 2026	2.64	2.99	2.62	2.91	985.15K
Jul 24, 2026	2.72	2.83	2.60	2.61	854.75K
Jul 23, 2026	2.59	2.78	2.49	2.68	1.61M
Jul 22, 2026	2.24	2.56	2.13	2.53	3.01M
Jul 21, 2026	2.25	2.30	2.19	2.23	307.75K
Jul 20, 2026	2.35	2.42	2.23	2.25	402.27K
Jul 17, 2026	2.23	2.39	2.18	2.36	380.41K
Jul 16, 2026	2.40	2.40	2.22	2.23	413.7K
Jul 15, 2026	2.30	2.47	2.27	2.43	513.55K
Jul 14, 2026	2.45	2.45	2.23	2.29	1.08M
Jul 13, 2026	2.65	2.68	2.42	2.44	942.85K
Jul 10, 2026	2.64	2.69	2.40	2.67	852.82K
Jul 09, 2026	2.69	2.81	2.59	2.64	723.45K
Jul 08, 2026	3.03	3.07	2.63	2.69	1.35M
Jul 07, 2026	2.47	3.20	2.37	3.07	2.46M

Contact Details

Boston, MA 02140

United States

https://www.pyxisoncology.com 617 221 9059

About Company

Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.

Stock Peers

ARGX

-23.03-2.70%

argenx SE$830.79 REGN

-3.39-0.44%

Regeneron Pharmaceuticals, Inc.$759.24 UTHR

-1.4-0.27%

United Therapeutics Corporation$516.31 MDGL

14.68+3.14%

Madrigal Pharmaceuticals, Inc.$482.00 VRTX

-6.335-1.33%

Vertex Pharmaceuticals Incorporated$470.77 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ONC

-2.24-0.71%

BeOne Medicines AG$313.77 KRYS

-28.55-8.37%

Krystal Biotech, Inc.$312.57 PRAX

-2.32-0.75%

Praxis Precision Medicines, Inc.$305.51 LGND

4.5+1.57%

Ligand Pharmaceuticals Incorporated$292.04

Frequently Asked Questions

What is the current Pyxis Oncology, Inc. (PYXS) stock price?

Pyxis Oncology, Inc. (NASDAQ: PYXS) stock price is $3.04 in the last trading session. During the trading session, PYXS stock reached the peak price of $3.04 while $2.70 was the lowest point it dropped to. The percentage change in PYXS stock occurred in the recent session was 14.72% while the dollar amount for the price change in PYXS stock was $0.39.

PYXS's industry and sector of operation?

The NASDAQ listed PYXS is part of Biotechnology industry that operates in the broader Healthcare sector. Pyxis Oncology, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of PYXS?

Mr. John L. Flavin M.B.A., MBA, Ph.D.
Co-Founder & Independent Chairman
Dr. Jan Pinkas Ph.D.
Chief Scientific Officer
Ms. Martina Molsbergen B.S.
Interim Chief Bus. Officer
Dr. Lara S. Sullivan M.D., MBA
Chief Executive Officer, Pres & Director
Dr. Jay M. Feingold M.D., Ph.D.
Chief Medical Officer
Dr. Charles T. Gombar Ph.D.
Senior Vice President of Portfolio & Program Management
Mr. Jitendra Wadhane
Chief Accounting Officer, Senior Vice President of Fin. & Corporation Controller
Ms. Pamela Yanchik Connealy M.B.A.
Chief Financial Officer & Chief Operating Officer
Dr. Balu N. Balasubramanian Ph.D.
Advisor

How PYXS did perform over past 52-week?

PYXS's closing price is 213.4% higher than its 52-week low of $0.97 where as its distance from 52-week high of $5.55 is -45.23%.

How many employees does PYXS have?

Number of PYXS employees currently stands at 56.

Link for PYXS official website?

Official Website of PYXS is: https://www.pyxisoncology.com

How do I contact PYXS?

PYXS could be contacted at phone 617 221 9059 and can also be accessed through its website. PYXS operates from 321 Harrison Avenue, Boston, MA 02140, United States.

How many shares of PYXS are traded daily?

PYXS stock volume for the day was 1.12M shares. The average number of PYXS shares traded daily for last 3 months was 986.03K.

What is the market cap of PYXS currently?

The market value of PYXS currently stands at $192.60M with its latest stock price at $3.04 and 63.36M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	56
Beta	1.31
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	56
Beta	1.31
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

PYXS Company Profile and Key Details

Pyxis Oncology

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Price Forecast & Outlook

Key Takeaways

Valuation Metrics